Headlands Technologies’s Denali Therapeutics DNLI Stock Holding History

Headlands Technologies’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,557	Closed	-$203K	–	780
2026 Q1	$203K	Sell	10,557 -35,826	-77%	-$713K	0.02%	594
2025 Q4	$766K	Buy	+46,383	New	+$783K	0.06%	312
2025 Q3	–	Sell	-1,847	Closed	-$25.8K	–	781
2025 Q2	$25.8K	Buy	+1,847	New	+$26K	﹤0.01%	891
2024 Q2	–	Sell	-4,295	Closed	-$88.1K	–	1237
2024 Q1	$88.1K	Buy	+4,295	New	+$80.7K	0.02%	572

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Headlands Technologies's DNLI Position: Q2 2026 in Review

Headlands Technologies sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 10,557 shares — an estimated $203K sold.

Headlands Technologies first reported a position in DNLI in Q1 2024 and held it in 4 quarters. The position peaked at $766K in Q4 2025. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Headlands Technologies reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
Headlands Technologies sold 10,557 Denali Therapeutics shares in Q2 2026, an estimated $203K.
Headlands Technologies first reported a position in Denali Therapeutics in Q1 2024 and held it in 4 quarters.
Headlands Technologies's Denali Therapeutics position peaked at $766K in Q4 2025.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.